Nabriva Therapeutics plc - Ordinary Shares (NBRV): Price and Financial Metrics


Nabriva Therapeutics plc - Ordinary Shares (NBRV)

Today's Latest Price: $0.68 USD

0.00 (-0.09%)

Updated Jul 2 4:00pm

Add NBRV to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NBRV Stock Summary

  • NBRV's price/sales ratio is 78.77; that's higher than the P/S ratio of 97.1% of US stocks.
  • With a year-over-year growth in debt of -69.2%, Nabriva Therapeutics plc's debt growth rate surpasses just 3.22% of about US stocks.
  • As for revenue growth, note that NBRV's revenue has grown 124.97% over the past 12 months; that beats the revenue growth of 95.41% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Nabriva Therapeutics plc, a group of peers worth examining would be FLDM, OBLN, TUFN, KALA, and AVGR.
  • Visit NBRV's SEC page to see the company's official filings. To visit the company's web site, go to www.nabriva.com.
NBRV Daily Price Range
NBRV 52-Week Price Range

NBRV Stock Price Chart Technical Analysis Charts


NBRV Price/Volume Stats

Current price $0.68 52-week high $2.77
Prev. close $0.68 52-week low $0.49
Day low $0.65 Volume 3,217,885
Day high $0.68 Avg. volume 4,223,048
50-day MA $0.71 Dividend yield N/A
200-day MA $1.28 Market Cap 969.26M

Nabriva Therapeutics plc - Ordinary Shares (NBRV) Company Bio


Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company was founded in 2006 and is based in Wien, Austria.


NBRV Latest News Stream


Event/TimeNews Detail
Loading, please wait...

NBRV Latest Social Stream


Loading social stream, please wait...

View Full NBRV Social Stream

Latest NBRV News From Around the Web

Below are the latest news stories about Nabriva Therapeutics plc that investors may wish to consider to help them evaluate NBRV as an investment opportunity.

CONTEPO CRL Is a Blow for Cash-Strapped Nabriva (NBRV), Says Analyst

The FDA’s equivalent of a red card – a CRL (complete response letter) – got handed out on June 19 to Nabriva Therapeutics (NBRV). Accordingly, the biotech’s share price has dropped nearly 15% since then.Nabriva might feel the market’s adverse reaction is a bit unfair. The company received the dreaded CRL for its complicated urinary tract infection (cUTI) treatment, CONTEPO, as a result of the FDA’s inability to inspect two of its manufacturing facilities due to coronavirus-induced travel restrictions.Nabriva already received a CRL for CONTEPO back in April of last year due to flaws at one of the company’s European CMOs (contract manufacturing organization).Before resubmitting CONTEPO’s NDA, Nabriva will request a meeting with the FDA to determine the next steps for the treatment’s road ...

Yahoo | June 24, 2020

CymaBay Seladelpar Data, And Other News: The Good, Bad And Ugly Of Biopharma

CymaBay Posts Positive Seladelpar Data for Bile Duct Disorder CymaBay Therapeutics (CBAY) reported upbeat data for its open label Phase 2 study of seladelpar for treating patients suffering from primary biliary cholangitis. Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta. The drug candidate has shown anti-inflammatory and anti-cholestatic...

Avisol Capital Partners on Seeking Alpha | June 23, 2020

Is Nabriva Therapeutics plc (NBRV) A Good Stock To Buy?

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]

Yahoo | June 22, 2020

Nabriva strikes out again on FDA nod for fosfomycin

Nabriva Therapeutics (NBRV) has received a CRL from the FDA in response to its refiled marketing application seeking approval of Contepo (fosfomycin) for the treatment of complicated urinary tract infections, including pyelonephritis (urinary tract infection that has traveled to the kidney).The reason for the rejection was the agency's inability to...

Seeking Alpha | June 20, 2020

Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injection

Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) resubmission seeking marketing approval of CONTEPO (fosfomycin) for injection for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis. Although Nabriva’s European contract manufacturing partners were prepared for regulatory authority inspections, the CRL cites observations at our manufacturing partners that could not be resolved due to FDA’s inability to conduct onsite inspections because of travel restrictions.

Yahoo | June 20, 2020

Read More 'NBRV' Stories Here

NBRV Price Returns

1-mo -13.78%
3-mo 29.35%
6-mo -45.16%
1-year -72.02%
3-year -93.43%
5-year N/A
YTD -48.48%
2019 -9.59%
2018 -75.59%
2017 0.34%
2016 -38.05%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.1356 seconds.